First-Line Faricimab in Diabetic Macular Edema: Insights from a Real-World Treatment-Naïve Population in Austria
Authors:
- Paul Widmann-SedlnitzkyPWPaul Widmann-Sedlnitzky
- Kim Lien HuberKHKim Lien Huber
- Irene SteinerISIrene Steiner
- Heiko StinoHSHeiko Stino
- Laura KunzeLKLaura Kunze
- Tilman SchmollTSTilman Schmoll
- Bianca S. GerendasBGBianca S. Gerendas
- Katharina KriechbaumKKKatharina Kriechbaum
- Stefan SacuSSStefan Sacu
- Andreas PollreiszAPAndreas Pollreisz
Open Access
- 13 May 2026
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3747
Abstract
Background: Diabetic macular edema (DME) is a leading cause of vision loss. Although real-world data on faricimab, a bispecific antibody targeting vascular endothelial growth factor-A and Angiopoietin-2, are expanding, its long-term durability in routine clinical practice has not yet been fully established. We evaluated effectiveness, anatomic response and treatment durability of first-line faricimab in treatment-naïve DME. Methods: We conducted a single-center, retrospective cohort study of treatment-naïve DME eyes initiated on intravitreal faricimab (August 2023–October 2024) in a real-world setting. After a loading phase, eyes were managed with a treat-and-extend or pro re nata regimen. The primary endpoint was retreatment interval at 48 weeks. Secondary endpoints were retreatment interval at weeks 12, 24 and 36; change in visual acuity (VA); central subfield thickness (CST); and optical coherence tomography (OCT) fluid. Results: Fifty-two eyes from 40 consecutive patients were included (baseline VA 65.96 ± 13.55 letters; CST 426.56 ± 106.72 µm). Mean injections were 4.02 ± 1.11 between months 1–6 and 1.90 ± 0.98 between months 7–12. VA improved by +8.46, +7.57, +7.65 and +7.72 letters at 12, 24, 36, and 48 weeks (all p < 0.0001), respectively. Relative CST decreased by −28.05%, −27.01%, −29.46% and −25.22% at the same time points (all p < 0.0001). At week 48, 15.4% of eyes were on a treatment interval of less than 12 weeks, 23.1% were between 12 and 16 weeks, and 46.1% were on 16 or more weeks; 15.4% were managed PRN. Conclusions: First-line faricimab in treatment-naïve DME in a real-world setting yielded clinically meaningful and durable extensions in treatment intervals, alongside sustained functional and anatomical improvements.Keywords
This publication has 32 references indexed in Scilit:
- Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular EdemaOphthalmology Retina, 2025
- Persistent diabetic macular edema: Definition, incidence, biomarkers and treatment methodsSurvey of Ophthalmology, 2022
- Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)Ophthalmology, 2020
- Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular EdemaOphthalmology, 2019
- Early Response to Anti–Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol TAmerican Journal of Ophthalmology, 2018
- Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edemaActa Diabetologica, 2018
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular EdemaOphthalmology, 2016
- Intravitreal Aflibercept for Diabetic Macular EdemaOphthalmology, 2014
- Ranibizumab for Diabetic Macular EdemaOphthalmology, 2012
- Diabetic retinopathyThe Lancet, 2010